![2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carbo…](https://static.cymitquimica.com/products/3D/img/FM102909.png "Cliquez pour agrandir")
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid
CAS : 1372540-25-4
Ref. 3D-FM102909
| 5mg | Arrêté | ||
| 10mg | Arrêté | ||
| 25mg | Arrêté |
Informations sur le produit
Nom :
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid
Description :
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid (BIC) is a strain that is categorized as a cancer drug. It has been synthesized in the laboratory and has been shown to bind to the bRaf protein, inhibiting its activity. BIC is also known as a stereoisomer because it has two different forms, L and D. The symbol for this drug is "BIC". This drug discriminates between healthy cells and cancer cells by selectively targeting those with mutated bRaf proteins. The parameter of this drug that is quantized is its effect on cancer cells. BIC's virulent effects may be due to its ability to inhibit the synthesis rate of antibodies in the body.
Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Biosynth
Stockage à long terme :
Notes :
Propriétés chimiques
Masse moléculaire :
433.42 g/mol
Formule :
C22H22F3N3O3
Degré de pureté :
Min. 95%
MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :
